B.Riley FBR analyst Andrew D’silva maintained a Buy rating on EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) on September 13 and set a price target of $5. The company’s shares closed on Friday at $2.20.
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 25.0% and a 55.7% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Oramed Pharmaceuticals, and Sorrento Therapeutics.
EyePoint Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.88, representing a 76.4% upside. In a report issued on September 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $2.50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.88 and a one-year low of $0.93. Currently, EyePoint Pharmaceuticals Inc has an average volume of 258.3K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EyePoint Pharmaceuticals, Inc. develops tiny, sustained-release products, which are designed to deliver drugs and biologics at a controlled and steady rate for weeks, months or years. The company through its technology platforms Duraser and Tethadur is focused on treatment of chronic diseases of the back of the eye and are also exploring applications outside ophthalmology. It is also developing a bioerodible, injectable micro-insert delivering latanoprost to treat glaucoma and ocular hypertension. The company was founded by Roger Aston in March 2008 and is headquartered in Watertown, MA.
